AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
IPO Year: 2016
Exchange: NASDAQ
Website: acimmune.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/31/2024 | $8.00 | Buy | BTIG Research |
| 12/20/2021 | $17.00 → $15.00 | Outperform | SVB Leerink |
BTIG Research initiated coverage of AC Immune with a rating of Buy and set a new price target of $8.00
SVB Leerink reiterated coverage of AC Immune with a rating of Outperform and set a new price target of $15.00 from $17.00 previously
HC Wainwright & Co. reiterated coverage of AC Immune with a rating of Buy and set a new price target of $16.00 from $11.00 previously
6-K - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
424B5 - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
EFFECT - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations100% of patients receiving ACI-7104.056 responded against the target antigenACI-7104.056 is well tolerated with no clinically relevant safety issues reported to date Lausanne, Switzerland, November 14, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and immunogenicity data from the Phase
AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 London Healthcare Conference, taking place in-person in London on November 19-21, 2024. The fireside chat will take place on November 20, 2024, at 6:00 AM (ET) / 11:00 AM (GMT). A webcast of the fireside chat will be available on the Events Page of AC Immune's website. A replay will be archived in the same locatio
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in SeptemberPotentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic ADFDA Fast Track designation granted in July for ACI-35.030 (now "JNJ-2056") for AD Lausanne, Switzerland, September 17, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment
AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer's disease by AC Immune's partner, LMIThis Fast Track designation applies across Alzheimer's disease, progressive supranuclear palsy, and corticobasal degenerationFollows two previous Fast Track designations for ACI-35.030 and ACI-24.060 active immunotherapiesAffirms AC Immune's leadership and commitment to bringing precision medicine to the management of neurodegenerative diseases Lausanne, Switzerland, August 28, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in CNS morADC demonstrated significant synergies, substantially increasing blood brain barrier penetration and potency to inhibit protein aggregation compared to the antibody or small molecule alone Lausanne, Switzerland, July 31, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today u
AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarterPhase 2b ReTain trial is fully funded and conducted by development partner Lausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of the Tau protein, phosphorylated Tau (pTau), has received Fast Track designation from the U.S. Food and Drug Administration (FDA). The recently init
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer's Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060, and ACI-19626 Lausanne, Switzerland, July 16, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer's Association International Conference (AAIC 2024), taking place in Philadelphia, PA, on July 28 - August 1, 2024. Pre
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024. The fireside chat will take place on Wednesday, June 5 at 3:30 PM (ET). A webcast of the fireside chat will be available at https://wsw.com/webcast/jeff30
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to host conference call and webcast today at 8:30 a.m. ET OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU)
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track for interim data in H2ACI-24.060 for Alzheimer's disease (AD) received FDA Fast Track designationACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partnerCash of CHF 103 million at year end, plus the CHF 15 million milestone payment received on February 1, 2024 and the next CHF 25 million ACI-35.030-related milestone, provides funding into 2026 Lausanne, Switzerland, March 14, 2024 – AC Immune SA (NASDAQ:ACIU
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to host conference call and webcast today at 8:30 a.m. ET OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU)
AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further develop its SAIT and monoclonal antibody for cardiovascular disease and for Huntington's disease, respectively VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS
All-stock transaction maintains AC Immune's strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune's therapeutic development in Parkinson's disease AC Immune to immediately launch clinical development of acquired vaccine into an adaptive, biomarker-based Phase 2 study in Parkinson's disease Conference call scheduled today at 8:30 am ET / 2:30 pm CET LAUSANNE, Switzerland, July 27, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it is acquiring Affiris' portfoli
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G - AC Immune SA (0001651625) (Subject)
SC 13G - AC Immune SA (0001651625) (Subject)
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handoverChristopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Off
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment of Nuno Mendonça, MD. He will join the Company on October 1st, as Chief Medical Officer and be appointed to the Executive Committee. Johannes Streffer, MD, currently Chief Medical Officer, will leave at the end of September to pursue a new role. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "It is with great pleasure that we welcome Dr Mendonça to our
Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a leading Swiss economist and former Vice President of the independent Swiss COVID-19 Science Taskforce LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. M
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain
Dr. Colowick has more than 20 years of experience in large and emerging biotech companies Led investments for several clinical-stage companies as a Partner at Sofinnova Investments LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Alan Colowick, MD, MPH, a deeply experienced biotech and investment executive, was elected to the Company’s Board of Directors at an extraordinary shareholders’ meeting today. Dr Colowick has more than 20 years of industry experience in both large and emerging biotech companies, serving in a broad a
U.S. stock futures were lower this morning, with the Dow futures falling around 250 points on Friday. Shares of RH (NYSE:RH) fell sharply in today's pre-market trading after the company reported mixed first-quarter financial results. RH reported quarterly losses of 40 cents per share which missed the analyst consensus estimate of losses of 12 cents per share. Quarterly sales came in at $726.96 million which beat the analyst consensus estimate of $724.7 million, according to data from Benzinga Pro. RH shares dipped 11.6% to $244.97 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Rezolute, Inc. (NASDAQ:RZLT) shares fell 19
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday. Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and upbeat second-quarter guidance. Ambarella posted adjusted loss of 26 cents per share, compared to market estimates for a loss of 31 cents per share. The company's quarterly sales came in at $54.473 million beating expectations of $53.875 million, according to data from Benzinga Pro. Ambarella shares jumped 23% to $59.42 on Friday. Here are some other big stocks recording gains in today's session. Latam Logistic Properties, S.A. (NYSE:LPA) shares jumped 79.5% to $464.77. The Ga
BTIG analyst Thomas Shrader initiates coverage on AC Immune (NASDAQ:ACIU) with a Buy rating and announces Price Target of $8.
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday. Shares of e.l.f. Beauty, Inc. (NYSE:ELF) rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter earnings. e.l.f. Beauty reported adjusted earnings of 53 cents per share, beating the 32-cent estimate, according to data from Benzinga Pro. Quarterly sales clocked in at $321.14 million, beating the $292.17 million analyst consensus estimate, primarily driven by strength across retailer and e-commerce channels. e.l.f. Beauty said it sees fiscal year earnings between $3.20 and $3.25 per share, versus the $3.51 per share estimate, and full-year revenue in a
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday. Shares of DLocal Limited (NASDAQ:DLO) fell sharply in today's pre-market trading after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood of coming in towards the lower end of its guidance range. DLocal posted GAAP earnings of 6 cents per share, compared to market estimates of 12 cents per share. The company's sales came in at $184.00 million missing expectations of $189.98 million, according to data from Benzinga Pro. DLocal shares dipped 26.6% to $9.97 in pre-market trading. Here are some big stocks recording loss
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 50 points on Monday. The Dow traded down 0.15% to 39,453.60 while the NASDAQ rose 0.21% to 16,375.08. The S&P 500 also fell, dropping, 0.06% to 5,219.74. Check This Out: JPMorgan, Global Payments And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsInformation technology shares rose by 0.7% on Monday. In trading on Monday, communication services shares fell by 1%. Top Headline GameStop Corporation (NYSE:GME) stock surged on Monday amid possible retail investor interest following a social media post by Roaring Kitty. Shares of struggling video game retailer GameSt